Join our 20.000 subscribers and receive the monthly newsletter for free!

RELATED ARTICLES
Costs for treatment of HIV

The University of Hasselt and the AIDS Reference Centre of Ghent University Hospital calculated that the treatment for people infected with HIV in…


Galapagos thinks big

Galapagos, the Mechelen biotech company, quit its inflammation alliance with Janssen under mutual agreement. Galapagos regained the proprietary ri…


Mithra to become the new Omega Pharma?

Businessman Marc Coucke has invested 40 million euros in the Liège pharmaceutical company Mithra. Coucke is now the second largest shareholder, be…

POPULAR TAGS

$12 million for Univercells's vaccines

Written by DS on in the category news with the tags , .


The Gosselies-based Univercells received a $12 million grant from the Bill & Melinda Gates Foundation for the development of a breakthrough vaccine manufacturing platform. The objective is to radically lower costs and increase vaccine availability and affordability in developing countries. The development will be performed by a consortium, including Batavia Biosciences and Natrix Separations.

Hugues Bultot, CEO and co-founder of Univercells says: “We are extremely honored to partner with the Gates Foundation to significantly increase global access to priority vaccines by lowering their manufacturing cost”.

The consortium will focus on developing  a manufacturing platform that integrates continuous processing with extremely high process intensification. This combination will allow miniaturization of commercial manufacturing to the point where it can be performed in local, low-cost micro-facilities.  The first target is to create a polio vaccine facility, that produces 40 million doses per year,  costing only 0.15$ per dose.

José Castillo, CTO and co-founder of Univercells, stated: “We are excited about this partnership with the Bill & Melinda Gates Foundation. With Batavia Bioscience and Natrix Separations, our consortium integrates considerable experience, know-how and innovative but proven technologies that tremendously increase manufacturing productivity. As a result, we expect our integrated platform to be a real game-changer for global health."

You might also be interested in "Bill & Melinda Gates Foundation Fund University of Antwerp's Polio Research"

Read more about the Bill & Melinda Gates Foundation

 

Read more about: , .

RELATED ARTICLES
Costs for treatment of HIV

The University of Hasselt and the AIDS Reference Centre of Ghent University Hospital calculated that the treatment for people infected with HIV in…


Galapagos thinks big

Galapagos, the Mechelen biotech company, quit its inflammation alliance with Janssen under mutual agreement. Galapagos regained the proprietary ri…


Mithra to become the new Omega Pharma?

Businessman Marc Coucke has invested 40 million euros in the Liège pharmaceutical company Mithra. Coucke is now the second largest shareholder, be…

POPULAR TAGS

Sign up to our Mailing List to receive updates
of our latest News, Events & Magazines

GSK Flanders.bio Turnstone XpandInnovation UGent Biowin Itera Life Science KU Leuven Janssen V-Bio Ventures

ABOUT BIOVOX - Sharing Life Sciences Innovations

BioVox showcases interesting life sciences breakthroughs for and from Belgian innovators. Through our partnership with BioCentury we share relevant worldwide innovations and business updates while our local journalists focus on regional highlights. 

Interested to get involved? Get in touch! We are looking for content, writers and partners! Blogs are available for research institutes, companies and freelance experts.

You want to reach out to the biotechnology and life sciences community, targetting selected audiences? Discover our sponsor and publication opportunities as well as tailored packages!

Contact BioVox via news@biovox.be or by completing the contact form.